Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Dec. 2025,
Poolbeg Pharma paid$0.01 Mil more to buy back shares than it received from issuing new shares.
It received$0.00 Mil from issuing more debt.
It paid$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received$0.00 Mil from paying cash dividends to shareholders.
It received$0.00 Mil on other financial activities.
In all, Poolbeg Pharmaspent$0.01 Mil on financial activities for the
six
months ended in Dec. 2025.
Poolbeg Pharma (OTCPK:POLBF) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Poolbeg Pharma's issuance of stock for the
six
months ended in Dec. 2025 was $-0.01 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Poolbeg Pharma's repurchase of stock for the
six
months ended in Dec. 2025 was $0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Poolbeg Pharma's net issuance of debt for the
six
months ended in Dec. 2025 was $0.00 Mil.
Poolbeg Pharma received$0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Poolbeg Pharma's net issuance of preferred for the
six
months ended in Dec. 2025 was $0.00 Mil.
Poolbeg Pharma paid$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Poolbeg Pharma's cash flow for dividends for the
six
months ended in Dec. 2025 was $0.00 Mil.
Poolbeg Pharma received$0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Poolbeg Pharma's other financing for the
six
months ended in Dec. 2025 was $0.00 Mil.
Poolbeg Pharma received$0.00 Mil on other financial activities.
Poolbeg Pharma Cash Flow from Financing Related Terms
Poolbeg Pharma Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Poolbeg Pharma's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poolbeg Pharma Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Poolbeg Pharma's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $6.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of $6.08 Mil mean?
Poolbeg Pharma (POLBF) has a Cash Flow from Financing of $6.08 Mil as of Dec. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Poolbeg Pharma and its competitors.
Is Poolbeg Pharma's Cash Flow from Financing too high?
Poolbeg Pharma's current Cash Flow from Financing is $6.08 Mil.
How does Poolbeg Pharma's Cash Flow from Financing compare to VRTX and REGN?
Poolbeg Pharma's Cash Flow from Financing of $6.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Poolbeg Pharma and its competitors. Poolbeg Pharma's current Cash Flow from Financing is $6.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Cash Flow from Financing of $6.08 Mil. The current Cash Flow from Financing is $6.08 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Cash Flow from Financing is $6.08 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
POLBF has been successfully added to your 